MiR-214 negatively regulates proliferation and WNT/β-catenin signaling in breast cancer
S.-J. Yi, L.-L. Li, W.-B. Tu General Surgery Department of Shenzhen University Affiliated Hospital, Shenzhen, China. sjyi2009@163.com
OBJECTIVE: To analyze the function and mechanism of miR-214 in regulating breast cancer cell proliferation.
MATERIALS AND METHODS: MiR-214 expression level was measured by quantitative reverse transcription Polymerase Chain Reaction (qRT-PCR). The protein level of β-catenin, PCNA and WNT targets (cyclin D1 and c-Myc) was evaluated by Western blot analysis. The effects of miR-214 on cell proliferation and cisplatin sensitivity were assessed by Cell Counting Kit-8 (CCK-8) assay and/or 5-bromo-2’-deoxyuridine (BrdU) assay. The effect of miR-214 on β-catenin and WNT signaling activity was tested by luciferase reporter assay.
RESULTS: MiR-214 was significantly downregulated in breast cancer tissues and was inversely correlated with β-catenin expression. Forced expression of miR-214 in breast cancer cell line MCF-7 led to a decrease in cell proliferation and an increase in cisplatin sensitivity. Moreover, forced expression of miR-214 decreased the activity of WNT luciferase reporter and the luciferase reporter containing the 3’-untranslated region (3’UTR) of β-catenin, whereas antisense inhibitor of miR-214 showed an opposite effect. Finally, miR-214 decreased the expression of β-catenin and multiple WNT target genes.
CONCLUSIONS: MiR-214 is downregulated and serves as a novel tumor suppressor in breast cancer. Forced expression of miR-214 in breast cancer cells diminished cancer cell survival possibly through inhibiting WNT signaling by direct repression of β-catenin.
Free PDF Download![Creative Commons License](https://i.creativecommons.org/l/by-nc-nd/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
To cite this article
S.-J. Yi, L.-L. Li, W.-B. Tu
MiR-214 negatively regulates proliferation and WNT/β-catenin signaling in breast cancer
Eur Rev Med Pharmacol Sci
Year: 2016
Vol. 20 - N. 24
Pages: 5148-5154